These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 34445729)
1. Doxorubicin Paradoxically Ameliorates Tumor-Induced Inflammation in Young Mice. Abdelgawad IY; Grant MKO; Popescu FE; Largaespada DA; Zordoky BN Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445729 [TBL] [Abstract][Full Text] [Related]
2. Slow infusion rate of doxorubicin induces higher pro-inflammatory cytokine production. Tien CC; Peng YC; Yang FL; Subeq YM; Lee RP Regul Toxicol Pharmacol; 2016 Nov; 81():69-76. PubMed ID: 27494949 [TBL] [Abstract][Full Text] [Related]
3. Sex-dependent alteration of cardiac cytochrome P450 gene expression by doxorubicin in C57Bl/6 mice. Grant MK; Seelig DM; Sharkey LC; Zordoky BN Biol Sex Differ; 2017; 8():1. PubMed ID: 28078076 [TBL] [Abstract][Full Text] [Related]
4. Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo. Yoshimoto Y; Kawada M; Ikeda D; Ishizuka M Int Immunopharmacol; 2005 Feb; 5(2):281-8. PubMed ID: 15652759 [TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of doxorubicin-loaded poly (ε-caprolactone)-b-poly (N-vinylpyrrolidone) micelles enhances antitumor effect in lymphoma. Hira SK; Mishra AK; Ray B; Manna PP PLoS One; 2014; 9(4):e94309. PubMed ID: 24714166 [TBL] [Abstract][Full Text] [Related]
6. HPMA-based biodegradable hydrogels containing different forms of doxorubicin. Antitumor effects and biocompatibility. Ríhová B; Srogl J; Jelínková M; Hovorka O; Buresová M; Subr V; Ulbrich K Ann N Y Acad Sci; 1997 Dec; 831():57-71. PubMed ID: 9616702 [TBL] [Abstract][Full Text] [Related]
7. Intracellular doxorubicin kinetics in lymphoma cells and lymphocytes infiltrating the tumor area in vivo: a flow cytometric study. Zaleskis G; Ho RL; Diegelman P; Maccubbin D; Ujházy P; Mihich E; Ehrke MJ Oncol Res; 1994; 6(4-5):183-94. PubMed ID: 7841541 [TBL] [Abstract][Full Text] [Related]
8. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting. Etrych T; Chytil P; Mrkvan T; Sírová M; Ríhová B; Ulbrich K J Control Release; 2008 Dec; 132(3):184-92. PubMed ID: 18534705 [TBL] [Abstract][Full Text] [Related]
9. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248). Mosure KW; Henderson AJ; Klunk LJ; Knipe JO Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510 [TBL] [Abstract][Full Text] [Related]
10. Protective effects of tannic acid on acute doxorubicin-induced cardiotoxicity: Involvement of suppression in oxidative stress, inflammation, and apoptosis. Zhang J; Cui L; Han X; Zhang Y; Zhang X; Chu X; Zhang F; Zhang Y; Chu L Biomed Pharmacother; 2017 Sep; 93():1253-1260. PubMed ID: 28738542 [TBL] [Abstract][Full Text] [Related]
11. Doxorubicin modulated clock genes and cytokines in macrophages extracted from tumor-bearing mice. Teixeira AAS; Biondo LA; Silveira LS; Lima EA; Batatinha HA; Diniz TA; Oliveira De Souza C; Comin J; Neto JCR Cancer Biol Ther; 2020 Apr; 21(4):344-353. PubMed ID: 31931676 [TBL] [Abstract][Full Text] [Related]
12. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136 [TBL] [Abstract][Full Text] [Related]
13. Improved antitumor activity and reduced myocardial toxicity of doxorubicin encapsulated in MPEG-PCL nanoparticles. Sun C; Zhou L; Gou M; Shi S; Li T; Lang J Oncol Rep; 2016 Jun; 35(6):3600-6. PubMed ID: 27109195 [TBL] [Abstract][Full Text] [Related]
14. Antitumor activity and toxicological properties of doxorubicin conjugated to [alpha],[beta]-poly[(2-hydroxyethyl)-L-aspartamide] administered intraperitoneally in mice. Cheng C; Xue W; Diao H; Xia S; Zuo L; He A; Gao F; Huang Z; Chen J; Zhang J Anticancer Drugs; 2010 Apr; 21(4):362-71. PubMed ID: 20468087 [TBL] [Abstract][Full Text] [Related]
16. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study. Cabeza L; Ortiz R; Prados J; Delgado ÁV; Martín-Villena MJ; Clares B; Perazzoli G; Entrena JM; Melguizo C; Arias JL Eur J Pharm Sci; 2017 May; 102():24-34. PubMed ID: 28219748 [TBL] [Abstract][Full Text] [Related]
17. Dual subcellular compartment delivery of doxorubicin to overcome drug resistant and enhance antitumor activity. Song YF; Liu DZ; Cheng Y; Liu M; Ye WL; Zhang BL; Liu XY; Zhou SY Sci Rep; 2015 Nov; 5():16125. PubMed ID: 26530454 [TBL] [Abstract][Full Text] [Related]
18. Temporary blockade of interferon-γ ameliorates doxorubicin-induced cardiotoxicity without influencing the anti-tumor effect. Ma P; Qin Y; Cao H; Erben U; Ni C; Qin Z Biomed Pharmacother; 2020 Oct; 130():110587. PubMed ID: 32763819 [TBL] [Abstract][Full Text] [Related]
19. Early biomarkers of doxorubicin-induced heart injury in a mouse model. Desai VG; C Kwekel J; Vijay V; Moland CL; Herman EH; Lee T; Han T; Lewis SM; Davis KJ; Muskhelishvili L; Kerr S; Fuscoe JC Toxicol Appl Pharmacol; 2014 Dec; 281(2):221-9. PubMed ID: 25448438 [TBL] [Abstract][Full Text] [Related]
20. In vivo effect of oracin on doxorubicin reduction, biodistribution and efficacy in Ehrlich tumor bearing mice. Hanušová V; Tomšík P; Kriesfalusyová L; Pakostová A; Boušová I; Skálová L Pharmacol Rep; 2013; 65(2):445-52. PubMed ID: 23744429 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]